<DOC>
	<DOCNO>NCT02358889</DOCNO>
	<brief_summary>The purpose study evaluate safety , biological activity pharmacodynamic effect repeat intravitreal dos hI-con1 0.3 mg administer monotherapy combination ranibizumab 0.5 mg compare ranibizumab 0.5 mg monotherapy treat patient choroidal neovascularization ( CNV ) secondary age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Study Evaluating Intravitreal hI-con1â„¢ Patients With Choroidal Neovascularization Secondary Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Males female race least 50 year age Active primary CNV secondary AMD study eye BCVA 70 24 letter ( bad 20/40 20/320 ) study eye Monocular patient patient BCVA 35 few letter ( 20/200 worse ) good see eye Any prior treatment CNV advance AMD study eye , except dietary supplement vitamins Any intraocular ocular surface surgery ( include cataract surgery laser procedure ) study eye within 3 month Vitrectomy study eye Hereditary chronic hemorrhagic coagulopathy condition ( i.e. , hemophilia )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>